Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations-Reference-Cited by-同舟云学术

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Published:2014-02-12 Issue:2 Volume:9 Page:e85245
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Liang Wenhua,Wu Xuan,Fang Wenfeng,Zhao Yuanyuan,Yang Yunpeng,Hu Zhihuang,Xue Cong,Zhang Jing,Zhang Jianwei,Ma Yuxiang,Zhou Ting,Yan Yue,Hou Xue,Qin Tao,Dinglin Xiaoxiao,Tian Ying,Huang Peiyu,Huang Yan,Zhao Hongyun,Zhang Li

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference44 articles.

1. Cancer statistics, 2010;A Jemal;CA Cancer J Clin,2010

2. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions;S Ramalingam;Oncologist,2008

3. Lung cancer;RS Herbst;N Engl J Med,2008

4. Treatment of non-small-cell lung cancer with erlotinib or gefitinib;VD Cataldo;N Engl J Med Mar,2011

5. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS);M Fukuoka;J Clin Oncol,2011

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacoinformational, basic and clinical studies of 7-hydroxymatairesinol in the context of searching for effective and safe therapeutic approaches to the treatment of mastopathy;Pharmacokinetics and Pharmacodynamics;2024-06-25

2. Lignan 7-hydroxymatairesinol in the context of post-genomic pharmacology;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2024-05-15

3. The impact of the national centralized drug procurement on the use of original and generic targeted anti- tumor drugs in Hohhot, China: an interrupted time-series analysis;2024-03-29

4. A fully validated LC‑MS/MS method for quantifying bevacizumab in plasma samples from patients with NSCLC and its implications in therapeutic drug monitoring;Oncology Letters;2024-03-22

5. Uncommon Blepharitis;Journal of Clinical Medicine;2024-01-25